EX-99.1 2 zeoscientifix_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZEO ScientifiX Strengthens South Florida’s Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation Operating from Nova Southeastern University’s Center for Collaborative Research, ZEO ScientifiX is expanding physician education, scientific collaboration, and regenerative biologic innovation as Florida emerges as a national life sciences hub. DAVIE, FLORIDA - July 21, 2026 - As Florida rapidly emerges as one of the nation’s leading destinations for biotechnology and life sciences, ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”) is strengthening its role within South Florida’s growing healthcare innovation ecosystem through regenerative biologic research, development, physician education, and scientific collaboration. Operating from Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, ZEO ScientifiX is positioned within one of the state’s expanding centers for biotechnology and scientific innovation. The Company is focused on advancing regenerative medicine by connecting emerging science with physicians and healthcare professionals working to bri…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Zeo ScientifiX Inc.
ZEOXOTCEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 21, 2026, ZEO issued a press release announcing its efforts to strengthen its role within South Florida’s healthcare innovation ecosystem through regenerative biologic research and development, physician education, and scientific collaboration.…
Company context
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products, including Zofin™, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X™ (“PPX™”), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (“RAAM Products”).